Biotech Values

[DewDiligence]

Management also noted that ACHN and GILD continue to do extensive preclinical work on 1095 just to ensure that none of the safety problems that plagued the prior NS4A antagonist exist in the new compound. There was no indication that there have been any potential preclinical safety issues, but no one specifically posed that question during Q&A. I'm starting to wonder if there may be some kind of issue though, given the possibility of yet another delay in starting the Phase I trial.

You should’ve trusted your instincts! Also see the bottom of #msg-36600712, where I noted that ACHN management “protested too much” about there being no problem with the drug on the 4Q08 CC.

Good luck.